Research Papers:

Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis

Yifan Tong, Zheyong Li, Yuelong Liang, Hong Yu, Xiao Liang, Hui Liu and Xiujun Cai _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:26671-26678. https://doi.org/10.18632/oncotarget.15793

Metrics: PDF 1328 views  |   HTML 1929 views  |   ?  


Yifan Tong1, Zheyong Li 2, Yuelong Liang2, Hong Yu2, Xiao Liang2, Hui Liu3, Xiujun Cai2

1Medical College of Zhejiang University, Hangzhou, China

2Department of General Surgery, Sir Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University, Hangzhou, China

3Department of Biological Treatment Research Center, Sir Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University, Hangzhou, China

Correspondence to:

Xiujun Cai, email: [email protected]

Keywords: TACE, overall survival, disease-free survival, hepatocellular carcinoma, AFP

Received: January 09, 2017     Accepted: February 17, 2017     Published: March 01, 2017


Background: Although the transcatheter arterial chemoembolization (TACE) was demonstrated to be an alternative treatment of hepatocellular carcinoma with favorable oncological effect, the benefit of postoperative adjuvant TACE was still controversial. The aim of this study was to evaluate the effect of postoperative TACE in hepatocellular carcinoma.

Results: The 1, 3, and 5–year overall and disease–free survival rates were comparable between Surgery+TACE and Surgery groups. In subgroup analysis, tumor size (≥ 5 cm) was detrimental to disease–free survival (p = 0.028) and an inferior tendency of overall survival was presented. Besides, repeated TACE for patients contributed to a poor disease–free survival (p = 0.005). While, postoperative adjuvant TACE improved the overall survival in patients with high preoperative alpha–fetoprotein or positive pathologically (p = 0.039 and p = 0.045).

Materials and Methods: The data were collected from consecutive patients between January 2010 and September 2014. After propensity score matching, baseline characteristics, overall and disease–free survival were compared between two groups. Subsequently, univariate and subgroup analysis were carried on.

Conclusions: Our study indicated that single postoperative adjuvant TACE was beneficial for selected patients of stage I with tumor less than 5 cm, or high preoperative alpha–fetoprotein in serum or positive of alpha–fetoprotein pathologically.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15793